Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
54.46
+0.33 (0.61%)
Feb 21, 2025, 4:00 PM EST - Market closed
Sanofi Revenue
In the year 2024, Sanofi had annual revenue of 44.29B EUR with 7.73% growth. Sanofi had revenue of 11.42B in the quarter ending December 31, 2024.
Revenue (ttm)
44.29B EUR
Revenue Growth
+7.73%
P/S Ratio
2.98
Revenue / Employee
534,352 EUR
Employees
82,878
Market Cap
136.42B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.29B | 3.18B | 7.73% |
| Dec 31, 2023 | 41.11B | 805.00M | 2.00% |
| Dec 31, 2022 | 40.30B | 1.13B | 2.88% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
SNY News
- 7 hours ago - Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease - GlobeNewsWire
- 3 days ago - Sanofi: OpenAI's Research Agents Could Lead To Explosive Growth - Seeking Alpha
- 3 days ago - Press Release: Sanofi and CD&R sign Opella share purchase agreement - GlobeNewsWire
- 8 days ago - Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report - GlobeNewsWire
- 9 days ago - Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study - GlobeNewsWire
- 15 days ago - Healthcare company Sanofi announces share buyback of up to 2 billion euros - Reuters
- 15 days ago - Press Release: Execution of a share buyback agreement for up to €2 billion - GlobeNewsWire
- 18 days ago - MITEM PHARMA Continues Its Mission to Protect the Interests of Patients Suffering From Rare and Lethal Diseases by Acquiring the FLISINT® Speciality from SANOFI - Business Wire